---
title: "Protagonist Therapeutics grants new hires options for 7,300 shares, RSUs for 1,975 shares at $136.64 strike price"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294871185.md"
description: "Protagonist Therapeutics granted inducement equity awards to two new hires on July 31, 2026. The package includes options for 7,300 shares and RSUs for 1,975 shares, with an exercise price of $136.64. Options vest over four years (25% after one year, then monthly), while RSUs vest 25% annually over four years."
datetime: "2026-08-04T20:52:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294871185.md)
  - [en](https://longbridge.com/en/news/294871185.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294871185.md)
---

# Protagonist Therapeutics grants new hires options for 7,300 shares, RSUs for 1,975 shares at $136.64 strike price

-   Protagonist Therapeutics granted inducement equity awards on July 31, 2026 to two newly hired employees. \* Awards total options for 7,300 shares, RSUs for 1,975 shares under its amended inducement plan. \* Options carry a $136.64 exercise price, matching the Nasdaq closing price on July 31. \* Options vest over four years: 25% after one year, remainder monthly over three years; RSUs vest 25% annually over four years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608041605ACCESSWRNAPR\_\_\_\_\_1201426) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [ACCS.US](https://longbridge.com/en/quote/ACCS.US.md)

## Related News & Research

- [Protagonist Therapeutics (PTGX) Swings To Net Income, Is The Valuation Too Expensive?](https://longbridge.com/en/news/295354544.md)
- [Protagonist Therapeutics (PTGX) Projected to Post Earnings on Wednesday](https://longbridge.com/en/news/294213749.md)
- [Soybeans Technical Analysis: 1200-1270 Resistance Level](https://longbridge.com/en/news/296201788.md)
- [Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 Shares](https://longbridge.com/en/news/290945808.md)
- [Grupo Casas Bahia board signs off on Q2 2026 interim financial statements](https://longbridge.com/en/news/296013513.md)